🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

RecruitingNAAges 18 Years - anyAllUniversity Medical Centre Ljubljana
NCT07043686 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study evaluates the effect and safety of Cerebrolysin administered during early rehabilitation in patients with moderate neurological impairment after acute ischemic stroke, conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, UMC Ljubljana.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Being able to perform ARAT test Signed informed consent Both sexes, age not specified Acute ischemic stroke confirmed by imaging NIHSS score 6-12 No prior stroke or disability (mRS 0 before stroke) \- Exclusion Criteria: Not being able to perform ARAT test * Previous stroke or disability (mRS \> 0) * The patient unable to understand instructions
💊

What it tests

  • Cerebrolysin treatment
  • Standard treatment (including neurorehabilitation) of acute ischemic stroke
📍

Where

1 site
UMC Ljubljana - Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT)
Ljubljana, Slovenia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy